Thank for your feedback, this will help us improve our content for you!
Ola Landgren, MD, PhD, of the Memorial Sloan Kettering Cancer Center, NY, gives his insight into the measurable residual disease (MRD) data from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest hemonc news and updates
Keep up to date with all the latest news with our monthly newsletter